Article
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Leukemia - 1 Mar 2017
Xia Y, Xu-Monette Z Y, Tzankov A, Li X, Manyam G C, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards K L, Hsi E D, Choi W W L, van Krieken J H, Huh J, Ponzoni M, Ferreri A J M, Møller M B, Parsons B M, Winter J N, Piris M A, Westin J, Fowler N, Miranda R N, Ok C Y, Li Y, Li J, Medeiros L J, Young K H
Abstract excerpt
PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.